Efficacy and factors associated with reactivation following intravitreal ranibizumab or conbercept for retinopathy of prematurity

PurposeTo compare the efficacy of intravitreal ranibizumab (IVR) and conbercept (IVC) treatment for retinopathy of prematurity (ROP) and to evaluate the risk factors associated with disease reactivation.MethodsIn this retrospective study, the medical records of infants with ROP treated with IVR or I...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Qiuhui Liu, Jing Li, Jiafen Liu, Suzhen Xie, Ge Mu, Huanhuan Zhao, Jiao Zheng, Xuelin Huang, Jianxun Wang
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Frontiers Media S.A. 2026-02-01
Cyfres:	Frontiers in Medicine
Pynciau:	anti-VEGF (vascular endothelial growth factor) conbercept ranibizumab reactivation ROP (retinopathy of preterm)
Mynediad Ar-lein:	https://www.frontiersin.org/articles/10.3389/fmed.2026.1754490/full
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!